- Home
- FEBO vs ERNA Comparison
FEBO vs ERNA Comparison
Compare FEBO & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- ERNA
- Stock Information
- Founded
- FEBO 1993
- ERNA 2018
- Country
- FEBO Hong Kong
- ERNA United States
- Employees
- FEBO N/A
- ERNA N/A
- Industry
- FEBO
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- ERNA Health Care
- Exchange
- FEBO Nasdaq
- ERNA Nasdaq
- Market Cap
- FEBO 12.7M
- ERNA 14.2M
- IPO Year
- FEBO 2023
- ERNA N/A
- Fundamental
- Price
- FEBO $1.12
- ERNA $0.19
- Analyst Decision
- FEBO
- ERNA
- Analyst Count
- FEBO 0
- ERNA 0
- Target Price
- FEBO N/A
- ERNA N/A
- AVG Volume (30 Days)
- FEBO 7.7K
- ERNA 453.6K
- Earning Date
- FEBO 06-17-2025
- ERNA 06-13-2025
- Dividend Yield
- FEBO N/A
- ERNA N/A
- EPS Growth
- FEBO N/A
- ERNA N/A
- EPS
- FEBO N/A
- ERNA N/A
- Revenue
- FEBO $17,110,653.00
- ERNA $535,000.00
- Revenue This Year
- FEBO N/A
- ERNA N/A
- Revenue Next Year
- FEBO N/A
- ERNA N/A
- P/E Ratio
- FEBO N/A
- ERNA N/A
- Revenue Growth
- FEBO 11.58
- ERNA 365.22
- 52 Week Low
- FEBO $0.93
- ERNA $0.15
- 52 Week High
- FEBO $17.68
- ERNA $2.63
- Technical
- Relative Strength Index (RSI)
- FEBO 43.81
- ERNA 32.65
- Support Level
- FEBO $1.11
- ERNA $0.17
- Resistance Level
- FEBO $1.40
- ERNA $0.25
- Average True Range (ATR)
- FEBO 0.12
- ERNA 0.02
- MACD
- FEBO -0.03
- ERNA -0.01
- Stochastic Oscillator
- FEBO 21.33
- ERNA 11.44
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care c principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.